4 Insights with Topic: 生物科技
China's biopharmaceutical industry is undergoing a landmark transformation, emerging from a period of profound recalibration to establish itself as a global powerhouse. Propelled by its talent, patient access, cost-efficient infrastructure, and catalysed by comprehensive government policies aimed at supporting the innovative drug value chain, the sector is experiencing a broad-based resurgence, with results beginning to show in earnings and valuations in the first half of the year. The journey, however, is just beginning, fueled by the impending global patent cliff and its strong value proposition: delivering high-quality, innovative medicines at an accelerated pace. This capability ensures China's biopharma sector an indispensable player in the global market, even in the face of possible geopolitical headwinds. In this article, we discuss about the leading innovators in the homegrown biotech landscape—companies well-represented in our Premia China New Economy ETF (3173/9173 HK) and Premia China STAR50 ETF (3151/9151/83151 HK), which have outperformed multiple benchmarks year-to-date and will continue to drive alpha returns for global investors, propelled by a revaluation trend driven by domestic policy tailwinds, strong external partnerships and a rising market value.
Oct 03, 2025
China markets witnessed strong rally since Oct 2022 trough upon China reopening and covid policy pivot, and we start to see investor flows rotating from offshore to A-shares which are expected to outperform with a longer run for rally. Where are we in China’s reopening trajectory? Who are the policy supported sector leaders well placed to outperform? These are the common questions frequently asked by our clients. In this article, we discuss the 10 most frequently asked questions that came up in our recent conversations with investors and allocators, and share more color about pockets of opportunities as China reopening evolves into the second act for economic growth recovery.
Mar 17, 2023
If we agree China may offer outperformance in 2023, then the next step is to figure out the right positioning to capture the alphas. Investors are now at a crossroad to decide whether China tech is still investible. On one hand, the Internet platforms, used to be the market leaders, may no longer be the high-growth candidates in future as shown by the recent sluggish financial results. On the other hand, technological advancement remains one of the government’s key agendas that should help support the sector. In this article, we would like to share how to identify the “right” tech exposure to capture the opportunities in China market.
Dec 13, 2022
